Last-Resort cancer therapy made available to patients with no other options
NCT ID NCT03601442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to CTL019, a cell therapy that reprograms a patient's own immune cells to attack cancer. It is for people with lymphoma or leukemia who have no other treatment choices and cannot join a clinical trial. The goal is to offer a potential benefit when standard options are exhausted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CTL019 (tisagenlecleucel), a type of cell therapy that uses a patient's own immune cells to fight cancer
- What this could lead to
- If successful, this program could offer a lifeline to patients with serious blood cancers who have run out of standard treatments.
- What could go wrong
- This is not a clinical trial but an early-access program, so data on safety and effectiveness is limited. The therapy may not work for everyone and carries risks like severe immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a Two-Drug combo keep aggressive lymphoma at bay?